Berkeley Capital Partners LLC Cuts Stake in Kenvue Inc. $KVUE

Berkeley Capital Partners LLC lowered its stake in shares of Kenvue Inc. (NYSE:KVUE) by 85.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,666 shares of the company’s stock after selling 61,375 shares during the quarter. Berkeley Capital Partners LLC’s holdings in Kenvue were worth $184,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of Kenvue by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock worth $4,052,913,000 after purchasing an additional 1,604,040 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Kenvue by 22.4% in the 3rd quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock worth $601,267,000 after purchasing an additional 6,781,640 shares during the period. Dimensional Fund Advisors LP lifted its stake in Kenvue by 13.5% in the third quarter. Dimensional Fund Advisors LP now owns 23,127,234 shares of the company’s stock valued at $375,377,000 after purchasing an additional 2,747,952 shares during the last quarter. Van ECK Associates Corp grew its holdings in Kenvue by 101.3% during the third quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock valued at $298,008,000 after purchasing an additional 9,240,434 shares during the period. Finally, Amundi grew its holdings in Kenvue by 21.6% during the third quarter. Amundi now owns 17,645,761 shares of the company’s stock valued at $277,012,000 after purchasing an additional 3,135,871 shares during the period. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 1.59% of the stock is currently owned by insiders.

Kenvue Stock Performance

Kenvue stock opened at $17.18 on Friday. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $24.35. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $32.98 billion, a PE ratio of 20.21, a price-to-earnings-growth ratio of 1.30 and a beta of 0.55. The firm’s 50 day simple moving average is $17.50 and its 200 day simple moving average is $17.32.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.24 EPS. As a group, analysts expect that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th will be paid a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.8%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Barclays decreased their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 14th. Citigroup cut their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Jefferies Financial Group cut Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Zacks Research raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Finally, Canaccord Genuity Group increased their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average target price of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.